Due to the prognostic and therapeutic impact of TP53 alterations (17p deletion and TP53 mutation) in CLL, the response of TP53-mutated cases to the new agents has been widely analyzed (summarized in Table 1) and recently reviewed [23]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.